Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0085580 (essential hypertension)
 14,686 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A group of 20 patients with primary hypertension (NT) were studied for the influence of six-week propranolol therapy on the secretion of immunoreactive insulin (IR-I), gastrin glucagon (IR-G) and pancreatic polypeptide (IR-PP) induced by a high-fat test meal. The results of the examination before the therapy were compared with examination of 10 healthy persons. Before the therapy, the patients with NT revealed a decreased reactivity of IR-PP to the food stimulus. After propranolol therapy, the authors found a significant change of glucagonemia profile and pancreatic polypeptide concentration induced by a test meal. The results of the examinations made suggest a direct or indirect participation of beta-adrenergic endings in the regulation of glucagon and pancreatic polypeptide secretion in patients with primary hypertension.
 ...
PMID:[Effect of propranolol therapy on the secretion of insulin, glucagon, gastrin and pancreatic polypeptide in patients with essential hypertension]. 269 15

Secretion of insulin, glucagon, gastrin and pancreatic polypeptide (PP) at basal and test meal stimulation conditions were investigated in 17 patients with essential hypertension (EH) before and after 12 months of treatment with prazosin and in 10 healthy subjects. Before prazosin therapy, patients with EH differ from healthy subject higher insulin and gastrin but lower PP secretion after test meal stimulation. 12 month therapy with prazosin enhanced insulin and suppressed gastrin secretion stimulated by test meal in comparison to the pretreatment values. Prazosin therapy did not influence significantly glucagon and PP secretion. Our results suggest, that long term prazosin treatment markedly influenced insulin and gastrin secretion in patients with EH.
 ...
PMID:[Effect of long term prazosin treatment on secretion of insulin, glucagon, gastrin, and pancreatic polypeptide in patients with essential hypertension]. 847 41